ImmunityBio Inc (IBRX)

[vinmantoo]

Bought again when blood is in the streets

I sold half of my NK before the merger at $34/share because I didn't know how the market would react after the merger. The issue for me is that the IBRX market cap iss really high for a company with no products on the market. It was something like $13 billion after the merger an even with the drop it is $9 billion. EXEL is my second highest position in my Biotech portfolio and its revenues will be well over $1 billion in 2021. The EXEL market cap is just over $7 billion and it just received US and European approval for Cabo in front line RCC. I own companies that have no revenues yet, like MGNX and TRIL but their market caps are only $1.7 and $1.1 billion, respectively. I also like IBRX and am close to buying more. We will see if the drop continues the rest for the week, and if so that could induce me to buy more.